Role of vitamin D receptor activators on cardiovascular risk

Area of Science:

• Nephrology
• Cardiology
• Endocrinology

Background:

• Cardiovascular complications are the leading cause of mortality in chronic kidney disease (CKD) patients.
• Vascular calcification and left ventricular hypertrophy (LVH) are prevalent in CKD, contributing to increased cardiac mortality.
• Hyperphosphatemia is a common cardiovascular risk factor in CKD, promoting vascular calcification and reducing vascular compliance.

Purpose of the Study:

• To evaluate the efficacy of active vitamin D compounds in managing cardiovascular complications in CKD patients.
• To explore novel vitamin D receptor activators with reduced impact on serum phosphorus levels.
• To investigate the combined strategy of strict phosphate control and specific vitamin D therapy for cardiovascular risk reduction in CKD.

Main Methods:

• Review of experimental data on active vitamin D compounds and their effects on LVH and serum phosphorus.
• Analysis of the impact of hyperphosphatemia on vascular calcification and compliance in renal patients.
• Assessment of newly available vitamin D receptor activators with lower hyperphosphatemic effects.

Main Results:

• Active vitamin D compounds can directly reduce left ventricular hypertrophy (LVH) in the myocardium.
• Some active vitamin D compounds can increase serum phosphorus as an adverse effect.
• New vitamin D receptor activators demonstrate a reduced effect on serum phosphorus levels.

Conclusions:

• Strict control of serum phosphate is essential for CKD patients.
• Active vitamin D compounds offer potential benefits for cardiovascular health in CKD.
• Combining phosphate control with novel vitamin D therapies lacking hyperphosphatemic effects may effectively treat cardiovascular complications in CKD.